Translating Mechanistic Insights into Precision Therapeutics
CELLTIUM develops precision therapeutics for CMT1A and related rare neurological disorders by linking disease biology to phenotypic drug discovery. Powered by its proprietary PRECISION™ platform, the company is building a pipeline of targeted therapeutic programs.
Precision CMT1A Pipeline
CMT1A is driven by increased PMP22 gene dosage, which leads to Schwann cell dysfunction and impaired myelination. CELLTIUM’s programs are designed to address core disease mechanisms and preserve or restore peripheral nerve function.
Using PRECISION™, its proprietary discovery platform, CELLTIUM identifies therapeutic candidates designed to address key drivers of CMT1A pathology and promote myelination and peripheral nerve function. Its lead program, CTM26, is a small-molecule candidate that has demonstrated preclinical efficacy in established severe CMT1A mouse models. Follow-on programs targeting complementary mechanisms of CMT1A pathology are expanding the pipeline.
PRECISION™ Platform
PRECISION™ is CELLTIUM’s proprietary neuro-phenomic discovery engine, combining disease-relevant neurological models, high-content phenotypic screening, and AI/ML-driven multimodal analytics. By translating disease biology into actionable therapeutic candidates, the platform accelerates target discovery, candidate prioritization, and lead optimization.
Advancing Toward the Clinic
Building on its preclinical foundation, CELLTIUM’s lead CMT1A program, CTM26, is advancing toward IND-enabling studies to support future regulatory submissions and clinical development.